Showing 1731-1740 of 3030 results for "".
Keep Your Dermatology Practice HIPAA Compliant With These 5 Photo Tips
https://practicaldermatology.com/topics/practice-management/keep-your-dermatology-practice-hipaa-compliant-with-these-5-photo-tips/20684/Recommendations for managing patient photos while preserving privacy.Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuTopical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).Maskne and Beyond: Effects on the Skin and Implications of Occlusion and Friction
https://practicaldermatology.com/topics/acne-rosacea/maskne-and-beyond-effects-on-the-skin-and-implications-of-occlusion-and-friction/23517/An update on the skin effects of mask-wearing.Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis Patients
https://practicaldermatology.com/topics/research-update/monoclonal-antibodies-restoring-healthy-skin-microbiome-atopic-dermatitis-patients/24566/Monoclonal Antibodies for Restoring a Healthy Skin Microbiome in Atopic Dermatitis PatientsPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.A Growing Neuromodulator Market: Daxxify Approved
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-growing-neuromodualtor-market-daxxify-approved/23797/Revance Therapeutics’ DaxibotulinumtoxinA-lanm is now approved to treat glabellar lines.Risks of Multiple Primary Melanomas
https://practicaldermatology.com/topics/practice-management/risks-of-multiple-primary-melanomas/21058/Studies offer clarity on risks and patterns after diagnosis, as well as survival outcomes.Dermatology and the ICD-10 Code Conundrum
https://practicaldermatology.com/topics/practice-management/dermatology-and-the-icd-10-code-conundrum/21372/EHRs equipped for ICD-10 can make the impending transition smooth for any practice.Dealing With Unhappy Cosmetic Patients
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/dealing-with-unhappy-cosmetic-patients/23870/Tips on avoiding and appeasing difficult patients.